Immune checkpoint therapy (ICT) has dramatically altered clinical outcomes for cancer
patients and conferred durable clinical benefits, including cure in a subset of patients …

Immunotherapy has changed the treatment landscape for cancer over the past decade.
Inhibitors of the immune checkpoint proteins cytotoxic T lymphocyte antigen (CTLA)-4 …

Abstract Immune-checkpoint-inhibitor (ICI)–associated myotoxicity involves the heart
(myocarditis) and skeletal muscles (myositis), which frequently occur concurrently and are …

The intimate relationship between the epithelium and immune system is crucial for
maintaining tissue homeostasis, with perturbations therein linked to autoimmune disease …

T cells can acquire a broad spectrum of differentiation states following activation. At the
extreme ends of this continuum are short-lived cells equipped with effector machinery and …

Loss of fertility is a major concern for female reproductive-age cancer survivors, since a
common side-effect of conventional cytotoxic cancer therapies is permanent damage to the …

Immune checkpoint inhibitors can stimulate antitumor immunity but can also induce toxicities
termed immune-related adverse events (irAEs). Colitis is a common and severe irAE that …

Immune-related adverse events (irAEs) associated with immune checkpoint inhibitor (ICI)
therapy may vary substantially in their clinical presentation, including natural history …

With immune checkpoint inhibitors (ICIs) becoming the mainstay of treatment for many
cancers, managing their immune-related adverse events (irAEs) has become an important …

Immune checkpoint receptors such as programmed cell death protein 1 (PD-1), cytotoxic T-
lymphocyte associated protein 4 (CTLA-4), lymphocyte-activation gene 3 (LAG-3), and T cell …